Unicycive CEO Shalabh K. Gupta Receives RSU Award (762,200 shares)

What Happened
Shalabh K. Gupta, CEO and director of Unicycive Therapeutics (UNCY), was granted 762,200 restricted stock units (RSUs) on 2026-05-14. The Form 4 reports this as an award (code A) with a reported price of $0.00 per share (a derivative award payable in common stock). This is a compensation grant, not a purchase or sale.

Key Details

• Transaction date: 2026-05-14; Form 4 filed: 2026-05-21 (filed after the typical 2-business-day window).
• Transaction type/code: Grant/Award (A); derivative RSU award.
• Shares/units: 762,200 RSUs; reported price $0.00.
• Vesting: RSUs vest 1/3 on each anniversary of the grant date for 3 years, subject to continued service (per footnote F1).
• Shares owned after transaction: Not disclosed in the provided filing.
• Filing timeliness: Filed 7 days after the transaction date (late relative to the usual 2-business-day Form 4 requirement).

Context
RSUs are a form of compensation that convert to common stock only as they vest; no shares were exchanged or sold at grant. Because this is an award rather than an open-market purchase, it primarily reflects compensation, not an immediate insider buy/sell signal. Retail investors should note the vesting schedule—shares become real ownership over three years—and that later sales of vested shares would appear in subsequent filings.